The acceptability and tolerability of buspirone were assessed in 100 anxiety patients in 6 typical family practice centres. Diagnosis of anxiety was performed by the family physicians in their normal practice in order to create a representative sample of anxiety patients from a family practice environment. Standard anxiety assessments (e.g. Hamilton Anxiety Scale and final global assessments) were performed before, during and after 4 weeks' treatment with buspirone. The family physicians' diagnosis of anxiety matched DSM III criteria in 86% of cases. Many anxiety symptoms manifested concurrently; 14 symptoms each occurred in 60% of the patients. The mean final dosage of bus pirone was 20.7 mg/day wifh a range of 7.5 to 60 mg/day. Global impressions indicated 70% of the patients were improved at least moderately by buspirone. Physician and patient final assessments showed 84 and 90% of patients, respectively, benefitted from treatment. Hamilton anxiety scores (total) were improved by 46% at week 4. Adverse effects were consistent with known labelled reactions, e.g. nausea, headache and dizziness. No adverse effects were evident in over 50% of patients. Buspirone was equal to or better than prior anxiolytic treatment in 60% of patients.Anxiety is a common emotional state aggravated by stressful situations encountered while performing the activities of daily living. It is generally perceived as unpleasant and can be either an adaptive or maladjustive response, and can also be a symptom of a psychiatric disorder that can compromise daily functioning. Epidemiological data indicate that approximately 8.3% of the population will suffer from an anxiety disorder at some time in their adult life (Regier et al. 1984).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.